ClinicalTrials.gg
RecruitingNCT05179889Updated Mar 19, 2026

Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

A Phase 2/3 interventional study of mFOLFIRINOX and mFOLFOX 6 in Colon Cancer Stage III, sponsored by Chungnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Chungnam National University Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2021, registered Dec 2021).
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Colonic Neoplasms with a site in Korea, Republic of — 14 open to participants now, 30 under way, 11 of them phase 3. Colonic Neoplasms · Korea, Republic of.

Planned enrollment
22nd of 66
308 · median 177
Started
2021
with 6 others
Phase 2/3
Only one
of the 83
Primary completion
2028-07
later than 23 of 29 live
Registered
60th of 83
by date
Lead sponsor
2 of 83
Chungnam National University Hospital

Among the 83 studies in Colonic Neoplasms with a site in Korea, Republic of, this one is the 22nd largest by planned enrollment of the 66 interventional ones that give a count, is one of 7 that started in 2021, is the only one in phase 2/3, reaches primary completion later than 23 of the 29 other live ones, and was the 60th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

14 of the 83 studies in Colonic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Colonic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer

Read the detailed description

After inclusion and exclusion criteria have been fulfilled and the patient consent has been obtained, the patient will be included and randomized to mFOLFIRINOX or mFOLFOX 6 with a 1:1 ratio.

Arm A: mFOLFIRINOX Arm B: mFOLFOX

03

Conditions studied

  • Colon Cancer Stage III

Browse trials for

Keywords

  • High risk stage III (pT4N1/2 or pTanyN2) colon cancer
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 20-70 years with an ≤ 2
  2. Age of 71-75 years with an ECOG = 0
  3. confirmed high-risk stage III colon adenocarcinoma (pT4N1 or pTanyN2)
  4. Curative radical resection (successful R0 resection) within 60 days before randomization
  5. Adequate organ functions

    • ≥ 2×106 cells/mL
    • ≥ 9.0 g/dL
    • ≥ 100×106 cells/mL
    • /aspartate aminotransferase ≤2.5 × times the (ULN)
    • Serum total ≤ 1.5 ULN
    • Alkaline phosphatase ≤ 2.5 × ULN
    • Serum creatinine ≤1.5 × ULN or > 50 mL/min (Cockcroft-Gault formula)
  6. Able to understand and willing to sign and date written voluntary form
  7. ≥ 5 years

Exclusion criteria

Exclusion Criteria:

  1. Distant
  2. Middle or lower rectal cancer of need for radiotherapy
  3. Postoperative complication of 3 or more grades of Clavien-Dindo classification
  4. Underlying disease or postoperative condition which is for chemotherapy
  5. Known reaction to any study treatment component
  6. Familial adenomatosis polyposis or hereditary non-polyposis colorectal cancer
  7. Inflammatory bowel disease
  8. Previous other which cannot be curatively treated
  9. Pregnancy or breast feeding
  10. Any other situation would exclude the patient from study based on the investigator's opinion
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
308 participants (estimated)

Study arms

  • Experimental
    Arm A

    mFOLFIRINOX

    Drug: mFOLFIRINOX

  • Active comparator
    Arm B

    mFOLFOX 6

    Drug: mFOLFOX 6

Interventions

  • DrugmFOLFIRINOX

    Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion\] 12 cycles per 2 weeks mFOLFOX 6 \[Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week

  • DrugmFOLFOX 6

    Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks

06

What researchers measure

Primary outcomes

  1. Disease free survival (DFS)

    the time from the date of operation to the date of the first recurrence or the death from any cause

    Time frame: 3 years after the operation

Secondary outcomes

  1. Overall survival (OS)

    the time from the date of operation to the date of the death from any cause

    Time frame: 3 years after the operation

  2. Incidence of treatment-related adverse events

    Toxicity of all grade and more than grade 3 based on CTCAE version 5.0

    Time frame: 3 years after the operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lee KH, Yang IJ, Ha GW, Lee J, Park YY, Lee SH, Lee JM, Bae JH, Park EJ, Kim H, Kim KY, An S, Kim IY, Kim JY. mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial. BMC Cancer. 2024 Mar 29;24(1):397. doi: 10.1186/s12885-024-11939-x. PubMed 38553680 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Jul 2028, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2021
First posted
Jan 6, 2022
StartActual
Jul 6, 2021
Primary completionEst.
Jul 5, 2028
CompletionEst.
Mar 15, 2031
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05179889
Lead sponsor
Chungnam National University Hospital
Responsible party
Kyung-ha Lee (Associate professor, Chungnam National University Hospital) — Principal investigator
First posted
Jan 6, 2022
Start date
Jul 6, 2021
Primary completion
Jul 5, 2028 (estimated)
Completion
Mar 15, 2031 (estimated)
Last update
Mar 19, 2026

Study contacts

Kyung Ha Lee
Contact
lllllkh@cnuh.co.kr
821042141415
Kyung Ha Lee
principal investigator · Chungnam National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion